112196-70-0

Upstream product

• 112196-69-7 {2-[4-(tert-Butyl-dimethyl-silanyloxy)-phenyl]-ethyl}-methyl-carbamic acid tert-butyl ester 
• 24424-99-5 di-tert-butyl dicarbonate 
• 13062-76-5 N-Methyltyramine hydrochloride 
• 370-98-9 N-methyltyramine 
• 788824-85-1 N-t-butoxycarbonyl-N-methyl-O-benzyltyramine 
• 112196-68-6 Boc-NH-CH₂CH₂C₆H₄-4-OTBS 
• 64318-28-1 N-t-butoxycarbonyl-tyramine 
• 51-67-2 tyrosamine 

Downstream Products

• 112219-54-2 3-(3-{4-[2-({(S)-2-[(S)-2-{[(S)-2-((R)-2-Amino-propionylamino)-propionyl]-methyl-amino}-3-(4-methoxy-phenyl)-propionylamino]-propionyl}-methyl-amino)-ethyl]-phenoxy}-phenyl)-propionic acid pentafluorophenyl ester; compound with trifluoro-acetic acid 
• 112196-73-3 methyl 3-<3-<4-(2-(methylamino)ethyl)phenoxy>phenyl>propanoate 
• 112196-71-1 methyl 3-<3-(4-(2-(tertbutoxycarbonylmethylamino)ethyl)phenoxy)phenyl>propanoate 
• 112196-47-1 (12R,15S,18S,21S)-18-(4-Methoxy-benzyl)-12,15,17,21,23-pentamethyl-2-oxa-11,14,17,20,23-pentaaza-tricyclo[24.2.2.1^3,7]hentriaconta-1⁽²⁹⁾,3⁽³¹⁾,4,6,26⁽³⁰⁾,27-hexaene-10,13,16,19,22-pentaone 
• 112196-75-5 3-(3-{4-[2-({(S)-2-[(S)-2-{[(S)-2-((R)-2-tert-Butoxycarbonylamino-propionylamino)-propionyl]-methyl-amino}-3-(4-methoxy-phenyl)-propionylamino]-propionyl}-methyl-amino)-ethyl]-phenoxy}-phenyl)-propionic acid 
• 112196-74-4 3-(3-{4-[2-({(S)-2-[(S)-2-{[(S)-2-((R)-2-tert-Butoxycarbonylamino-propionylamino)-propionyl]-methyl-amino}-3-(4-methoxy-phenyl)-propionylamino]-propionyl}-methyl-amino)-ethyl]-phenoxy}-phenyl)-propionic acid methyl ester 
• 112196-78-8 3-(3-{4-[2-({(S)-2-[(S)-2-{[(S)-2-((R)-2-tert-Butoxycarbonylamino-propionylamino)-propionyl]-methyl-amino}-3-(4-methoxy-phenyl)-propionylamino]-propionyl}-methyl-amino)-ethyl]-phenoxy}-phenyl)-propionic acid pentafluorophenyl ester 
• 112196-77-7 3-(3-{4-[2-({(S)-2-[(S)-2-{[(S)-2-((R)-2-Amino-propionylamino)-propionyl]-methyl-amino}-3-(4-methoxy-phenyl)-propionylamino]-propionyl}-methyl-amino)-ethyl]-phenoxy}-phenyl)-propionic acid; compound with trifluoro-acetic acid 

Relevant academic research and scientific papers

Selective Monomethylation of Amines with Methanol as the C1 Source

The N-monomethyl functionality is a common motif in a variety of synthetic and natural compounds. However, facile access to such compounds remains a fundamental challenge in organic synthesis owing to selectivity issues caused by overmethylation. To address this issue, we have developed a method for the selective, catalytic monomethylation of various structurally and functionally diverse amines, including typically problematic primary aliphatic amines, using methanol as the methylating agent, which is a sustainable chemical feedstock. Kinetic control of the aliphatic amine monomethylation was achieved by using a readily available ruthenium catalyst at an adequate temperature under hydrogen pressure. Various substrates including bio-related molecules and pharmaceuticals were selectively monomethylated, demonstrating the general utility of the developed method.

Irreversible Cysteine-Selective Protein Labeling Employing Modular Electrophilic Tetrafluoroethylation Reagents

Fluoroalkylation reagents based on hypervalent iodine are widely used to transfer fluoroalkyl moieties to various nucleophiles. However, the transferred groups have so far been limited to simple structural motifs. We herein report a reagent featuring a secondary amine that can be converted to amide, sulfonamide, and tertiary amine derivatives in one step. The resulting reagents bear manifold functional groups, many of which would not be compatible with the original synthetic pathway. Exploiting this structural versatility and the known high reactivity toward thiols, the new-generation reagents were used in bioconjugation with an artificial retro-aldolase, containing an exposed cysteine and a reactive catalytic lysine. Whereas commercial reagents based on maleimide and iodoacetamide labeled both sites, the iodanes exclusively modified the cysteine residue. The study thus demonstrates that modular fluoroalkylation reagents can be used as tools for cysteine-selective bioconjugation.

SHORT ACTING PHENYLALKYLAMINE CALCIUM CHANNEL BLOCKERS AND USES THEREOF

The present invention relates to the use of a pharmaceutically effective amount of an short-acting calcium channel blocking compound to treat ischemic heart conditions, cardiac arrhythmias, hypertensive crisis in an emergency room setting, hypertension before, during, or after surgery, no- reflow phenomenon following reperfusion, and diseases associated with decreased skeletal muscle blood flow. The invention also relates to pharmaceutical compositions formulated for use in such methods and to kits for such methods.